Meddihub to Finalize the Lunch of Its App in Spain

New telemedicine service in Spain. Meddihub, a medical telecare company based in Prague,  will open the market in Spain at the end of 2023 and will introduce its app, which connects patients with a medical team through video calls, calls, or messages.

The company continuously monitors patients through its application, which monitors the vital signs of users, so that doctors can have complete information about patients at all times. Currently, the company has more than a thousand registered healthcare professionals in Europe and more than 1,500 in Latin America.

In addition to monitoring patient data, Meddihub acts as an intermediary between the two parties: the professionals are the ones who set the price for each consultation. The app generates income through the disbursement of health professionals, who pay to form Meddihub and must submit a periodic report on the condition of the patients.

Read more details about the telemedicine company Meddihub and find the latest business headlines of the day with our companion app. The Born2Invest mobile app keeps its readers up to date with the most important market updates.

Meddihub was founded in 2017 by Peter Jerisic in the Czech Republic

Nakari Ríos, project director of Meddihub Latin America, explained to PlantaDoce that “the official arrival in Spain will take place at the end of this year, but we have already held conventions and conferences to learn a little more about the country’s healthcare market.”

The company was founded in 2017 in the Czech Republic by Peter Jersic. Currently, it has a presence in more than fifteen countries in Europe. The last European country it landed in was Ukraine, where the company offers its services for free due to the war surrounding the country.

The app also has a presence in four Latin American countries: Peru, Ecuador, Colombia, and Venezuela. One of the company’s main objectives is that patients can be cared for by doctors from other countries, if required, with special emphasis on emigrants or exiles.

After landing in Spain, the company is already looking at the US market

One of the projects that Meddihub has carried out in recent months is the  BioScan method. This tool allows for measuring the health of the patient through a  selfie, which allows for measuring blood pressure, oxygen level, and glucose.

Currently, the company has more than a thousand health professionals in its portfolio in Europe and more than 1,500 in Latin America.

After landing in Spain, Meddihub is now seeking to enter the US market. “The United States has a weak health system where patients have to travel long distances to be treated,” said Ríos, who pointed out that “telemedicine costs 30% to 50% less than conventional medicine.”

__

(Featured image by Edward Jenner via Pexels)

DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of Born2Invest, its management, staff, or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.